The Real Story behind Antimicrobial Resistance – Part II

The Real Story behind Antimicrobial Resistance – Part II

“The current U.S. healthcare system and its orientation towards drug cures developed through guided funding by the RockefellerFoundation – started in 1926 to provide “pharmaceutical oriented training and development” to U.S. medical schools.The Foundation provided grants only to medical schools which agreed to focus on drug-cures and pharmaceutical dispensing training for its doctors and residents. The Rockefeller family simultaneously invested in a few major drug companies, including substantially funding,assisting and helping the company responsible for the German (Nazi) War Effort – I.G. Farben.

The origins of American healthcare becameheavily oriented towards the cure of diseases, not the prevention of diseases. A vast “clockwork orange” developed, both inside the U.S. government (Food and Drug Administration; Centers for Disease Control; National Institutes of Health) to promote and purvey a specific approach to health, based on curing but not preventing disease, and outside the government – the few key large pharmaceutical companies. ” (Gene Rosov, Pres., Io Products, Inc.)

To see the details of how the Rockefeller Foundation, the Rockefeller family, the U.S. banking system and the U.S. Federal Reserve helped, indeed, propelled the Nazi war machine, please visit this electrifying description of recorded hearings in the U.S. Senate, House Un-American Activities Committee:, led by Senator Homer T. Bone (Senator from Washington state) to the U.S. Senate Committee on Military Affairs, June 4, 1943, during the course of the IInd World War.
You just can’t make this stuff up. It’s mind-blowing, and faith-shattering. Read it

In simple summary, Senator Bone testified: “Without the capital supplied by Wall Street, there would have been no I. G. Farben (the major German chemical and pharmaceutical company) in the first place and almost certainly no Adolf Hitler and World War II.”

It is the same I.G. Farben that produced all the gas to murder Jews in concentration camps, and which launched the 20th century’s first major pharmaceutical operations. Farben resources were purchased, eventually, by U.S. drug manufacturer Merck & Co. These resources included Bayer – which is now on the eve of purchasing U.S. Monsanto Chemical.

I mentioned in the last blog that I’d attended a CDC (Centers for Disease Control) meeting about anti-microbial resistance in healthcare facilities. It reminded me of the cartoon above that opens today’s blog, Part II. What I heard was that we are trying, unsuccessfully, to get doctors to change their prescribing habits. I suspect that the physicians attending, and the organizations sponsoring this event, spent many, many tens of thousands of dollars on the programs described. Result: not very successful. As the wise worms in the cartoon above indicate, it’s all just talk. And expensive talk at that.
cdcIt also begs the key question: Will the CDC changing doctors’ prescribing habits alter the course of antimicrobial resistance? My suspicion is that it will not. Only an orientation towards good health and prevention will change the course of antimicrobial resistance.

The webinar described to the attendees the procedures that some hospital s are putting in place – to reduce the usage of antibacterial/anti-microbial drugs. The bad news: it is very hard to get doctors to stop prescribing pills, and equally hard to get them to take “time out” to consider/re-consider whether the drug is the right drug (the patient responds), or the drug isn’t working.

We tend to think of medicine as a fairly cut-and-dry expertise. You have these symptoms, it’s this disease, here’s the pill for it, see me in a week. Nothing…and I mean NOTHING….could be further from the truth. Everyone is unique, every disease is unique, and the “framework” – your body, your immune system, your diet, your genetics, your environment – is just as important as the drug vs. the bug. Often, it’s MORE important. No kidding.
cdcIn 2013, it was reported that “the U.S. Centers for Disease Control and Prevention (CDC) says millions of Americans are at risk from drug-resistant superbugs that cause gonorrhea, C. difficile, and carbapenem-resistant Enterobacteriaceae (CRE). The CDC report said that at least 2 million people in the United States each year develop bacterial infections that are resistant to one or more types of antibiotics—and at least 23,000 will die from the infections.”[That number is now up to 99,000 – better measurements, greater honesty, or increases in actual death?]

“Antibiotic resistance is rising for many different pathogens that are threats to health,” said CDC Director Tom Frieden, MD, MPH. “If we don’t act now, our medicine cabinet will be empty and we won’t have the antibiotics we need to save lives.” Experts attribute the problem to overprescribing, as pathogens adjust to the drugs used to treat them. Few companies are working to drugs to replace the once-potent antibiotics.

Carbapenem resistant enterococcae or CRE Frieden calls a “nightmare bacteria” that is resistant to the strongest antibiotics. About 9,300 CRE infections are reported each year and it causes 600 deaths annually, according to the report. Almost half of hospital patients who get bloodstream infections from CRE bacteria die. C. difficile, the most common hospital-based infection in the United States, causing 250,000 infections and killing 14,000 people each year. The CDC report said C. difficile has begun to resist antibiotics and is aided by the overuse of antibiotics. It causes life-threatening diarrhea and can spread from person to person via equipment, healthcare workers, or visitors. Deaths from C. difficile rose 400% from 2000 to 2007. Drug-resistant Neisseria gonorrhoeae. There are more than 300,000 reported cases of gonorrhea that are resistant to any antibiotic, which is almost one third of cases (820,000) estimated in the United States. Traditionally, gonorrhea is treated with tetracycline, cefixime, ceftriaxone, and azithromycin. The CDC said N. gonorrhoeae has become resistant to these medications.” (Comment: Don’t have unprotected sex if you want to remain alive.)

antimicrobial resistance

At the turn of the last century, around 1913 (after losing a Supreme Court battle in which his Standard Oil company was supposed to be dismantled – but it never was), John D. Rockefeller started the Rockefeller Foundation. Its goal was to fund medical school programs in drug therapy. It was enormously successful, and succeeded in oriented the medical industry towards cure, but not prevention. Cure – especially partial cure – is extremely profitable. For example, according to the CDC Foundation (formed by Congress to assist the CDC itself), heart disease alone is costing the U.S. taxpayer nearly one BILLION dollars a day – projected to be annually one trillion dollars by 2030, or about 25% of the total current U.S. federal budget. (The CDC Foundation says that heart disease is “almost totally preventable!”) Add obesity, cancer and chronic obstructive pulmonary disease, and we’re approaching TWO TRILLION dollars (50% of the U.S. annual budget today). Why is it so huge, why are we so sick? rockefellerIt is enormously profitable for hospitals and drug companies for us to be ill….the longer we live, the more we spend on drugs. Yes, we’re living longer but it’s a two-edged sword. The idea: keep us alive, relatively stable (if miserable), and always on pills. Beneficiaries include hospitals, nursing homes, clinics. It’s highly profitable.

But: the antibiotic pill business isn’t profitable. Cancer, heart disease, obesity, COPD, dental cavities, genetic abnormalities – these are very profitable. But infectious diseases are treated, and then go away. Little investment has been made in new drugs. There hasn’t been a major new drug since the carbapenems. While successful against multi-drug-resistant organisms, carbapenems (there are several) now experience significant resistance.
These problems with drug resistance have caused the United Nations, and a senior U.N. health official, to underline the need for all medical sectors to address an “urgent global threat, which has the potential to undermine sustainable development.” Here’s what that means….(this is directly from the MDLinx Washington Report)…..

Before we quote it, though, just keep in mind: iodine produces NO antimicrobial resistance; it kills ALL known dangerous microbes; it is safe both topically and enterically (by ingestion). It can cure diabetes, help cardiovascular disease and obesity and cancer. The problem for drug companies: it cannot be patented, and it is very cheap. It will NEVER be used by the U.S. drug companies, as they cannot make money from it. But…YOU can use it. And your physician is very likely open to this discussion.

doctorIodine is, we believe, a potential “silver bullet” against the problem of antimicrobial resistance. Why will it not be taken up by the medical community and hospitals, clinics and nursing homes? It’s cheap, effective and easily monitored. But it’s not controlled by pharmaceutical providers.\

Antimicrobial resistance occurs when microorganisms (such as bacteria, fungi, viruses, and parasites) change/evolve as they are exposed to drugs (such as antibiotics, antifungals, antivirals, antimalarials, and anthelmintics) used to treat the infections they cause. These are sometimes referred to as “superbugs.” As a result, the medicines become ineffective and infections persist in the body – which increases the risk of a disease organism spreading to others.

Here’s the MDLinx Washington Report piece. Again, you can’t make up this stuff. It’s just way too terrifying. If you like zombies, you’re going to love this:

“The emergence of antimicrobial resistance really threatens to send us backwards – to have infections once again become a much larger killer of people,” said Dr. Keiji Fukuda, Assistant Director–General of the World Health Organization (WHO) and Special Representative for Antimicrobial Resistance.
“By 2050, estimates indicate more people could die from antibiotic–resistant infections than those who currently die from cancer. This is a surprising comparison; it means that almost 10 million people would die from infections because they those couldn’t be treated anymore,” he added.

Dr. Fukuda also pointed out that the economic cost of such a scenario would also be staggering, and warned that the cumulative economic loss on having to take care of people suffering from such infections and possible subsequent deaths could exceed $100 trillion by 2050. “This is on the order of 2 to 3.5 per cent of the global GDP – enough to send countries backward, particularly those that are in precarious economic conditions,” he said, adding that, even more importantly, such economic setbacks could deprive medical and health systems of the resources needed to take care of and treat people.
FukudaFurthermore, noting that sustainable food supplies depend heavily on antibiotics because they are used to treat sick animals and prevent the spread of diseases, Dr. Fukuda said that with rising global populations, availability of food to feed everyone would depend heavily on the efficacy of antibiotics.

Dr. Fukuda stressed that eroding healthcare and the inability to feed people, compounded by enormous economic cost, could potentially take away countries’ ability to continue with development, in particular sustainable development.

By discussing antimicrobial resistance next week at the high–level meeting, Dr. Fukuda said, heads of state and government would be sending a very visible sign that they understand the gravity of the situation and are committed to addressing it. The meeting will help facilitate concrete coordination among different sectors and help implement it in practice, and will also help secure the engagement and support of multiple sectors which are vital to address such a complex, global challenge, Dr. Fukuda emphasized.
President of the UNThe High–Level Meeting on Antimicrobial Resistance, convened by the President of the UN General Assembly, WHO, and the UN Food and Agriculture Organization (FAO), will be held on September 21, 2016 on the sidelines of UN General Assembly’s 71st session.

Leave a Comment